1. Coleman RE. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). Breast Cancer. 2000; 7:361–369. PMID:
11114866.
2. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002; 20:3719–3736. PMID:
12202673.
Article
3. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350:1189–1199. PMID:
15028823.
Article
4. Park HM, Lee ES, Kim SM. The use of osteoporosis medications in Korea in 2008. J Bone Metab. 2009; 16:87–93.
5. Miller PD. The kidney and bisphosphonates. Bone. 2011; 49:77–81. PMID:
21232648.
Article
6. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996; 18:75–85. PMID:
8833200.
Article
8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61:1115–1117. PMID:
12966493.
Article
9. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2–12.
10. Silva PG, Ferreira Junior AE, Teófilo CR, Barbosa MC, Lima Júnior RC, Sousa FB, et al. Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis. Arch Oral Biol. 2015; 60:1237–1245. PMID:
26093347.
Article
11. Manzano-Moreno FJ, Ramos-Torrecillas J, De Luna-Bertos E, Ruiz C, García-Martínez O. High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. J Craniomaxillofac Surg. 2015; 43:396–401. PMID:
25614214.
Article
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1–S266. PMID:
11904577.
13. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67:2089–2100. PMID:
15882252.
Article
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150:604–612. PMID:
19414839.
Article
15. Park JC, Rhee SH, Kim YH, Kang MS, Son YH, Kim HG, et al. The effectiveness of the surgical approach and drug-holiday on the treatment of bisphosphonate related osteonecrosis of the jaw patient. Int J Oral Maxillofac Surg. 2015; 44(Suppl 1):e275.
Article
16. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008; 74:721–731. PMID:
18563052.
Article
17. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41:1–12. PMID:
12500213.
Article
18. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22:1479–1491. PMID:
17663640.
Article
19. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update. J Oral Maxillofac Surg. 2014; 72:1938–1956. PMID:
25234529.
20. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007; 18:2758–2765. PMID:
17855638.
21. Gifre L, Peris P, Monegal A, Martínez-Ferrer A, Hernández MV, Guañabens N. Effect of bisphosphonates on renal function in patients with osteoporosis. Eur Geriatr Med. 2013; 4:380–383.
Article
22. Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg. 2013; 39:9–13. PMID:
24471011.
Article
24. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65:415–423. PMID:
17307586.
Article
25. Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent. 2013; 61:33–38.
26. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65:2397–2410. PMID:
18022461.
Article
27. Song JW, Kim KH, Song JM, Chun BD, Kim YD, Kim UK, et al. Clinical study of correlation between C-terminal cross-linking telopeptide of type I collagen and risk assessment, severity of disease, healing after early surgical intervention in patients with bisphophonate-related osteonecrosis of the jaws. J Korean Assoc Oral Maxillofac Surg. 2011; 37:1–8.
Article
28. Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010; 141:1365–1370. PMID:
21037195.
29. Park W, Kim NK, Kim MY, Rhee YM, Kim HJ. Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int. 2010; 21:527–533. PMID:
19484166.
Article
30. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23:8580–8587. PMID:
16314620.
Article
31. Hoff A, Toth B, Altundag K, Guarneri V, Adamus A, Nooka A, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol. 2006; 24:8528.
Article
32. Baqain ZH, Sawair FA, Tamimi Z, Bsoul N, Al Edwan G, Almasad JK, et al. Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl. 2010; 92:489–494. PMID:
20522306.
Article
33. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009; 27:5356–5362. PMID:
19805682.
Article
34. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001; 12:1164–1172. PMID:
11373339.
Article
35. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003; 64:281–289. PMID:
12787420.
Article
36. Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford). 2014; 53:19–31. PMID:
23838024.
Article
37. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139:137–147. PMID:
12859163.
Article